Experts: India’s New IP Policy Shows Good Intent But Needs Timelines
This article was originally published in PharmAsia News
Executive Summary
A group representing multinational pharmaceutical companies in India has praised the government's new national intellectual property rights policy for embracing a "culture of innovation" but says the policy needs more teeth to truly protect patents and trademarks.
You may also be interested in...
India Will Miss Investment Boat If New IPR Policy Just All Talk
India’s more muscular intellectual property protection policy is a good first step but the government will have to “walk the talk” to attract significant new investment from global pharmaceutical companies, say US experts. Implementation of the policy will be the key measure of its success, they say.
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.